CTIS2024-514581-39-00
Active, not recruiting
Phase 1
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of theChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.
Ospedale San Raffaele S.r.l.0 sites33 target enrollmentJuly 12, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- HIV Infection
- Sponsor
- Ospedale San Raffaele S.r.l.
- Enrollment
- 33
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1/2
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of the
ChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.2024-514581-39-00Ospedale San Raffaele S.r.l., Ospedale San Raffaele S.r.l.33
Active, not recruiting
Not Applicable
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.EUCTR2010-018770-20-NOOslo University Hospital30
Completed
Phase 1
Phase I study safety and immunogenicity of vaccination with XAGE1 long peptides in patients with advanced lung adenocarcinomaAdvanced lung adenocarcinomaJPRN-UMIN000026493Department of Immuno-Oncology, Kawasaki Medical School10
Completed
Phase 1
Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent pancreatic cancer to be refractory to chemotherapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatioJPRN-UMIN000002022Department of Gastroenterology, Juntendo University School of Medicine36
Completed
Phase 1
Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent gastric cancer to be refractory to chemotherapy by using new tumor antigen URLC10 and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatiogastric cancerJPRN-UMIN000002409Department of Gastroenterology, Juntendo University School of Medicine36